期刊文献+

Nanoparticles as a vaccine adjuvant of anti-idiotypic antibody against schistosomiasis 被引量:5

Nanoparticles as a vaccine adjuvant of anti-idiotypic antibody against schistosomiasis
原文传递
导出
摘要 Background The development of new adjuvants for human use has been the focus of attention. This study’s aim is to explore the possibility of using nanoparticle Ca nanoparticles (CA) as a vaccine adjuvant of anti-idiotypic antibody NP30 against schistosomiasis and its protective mechanisms. Methods Nanoparticle CA-NP30 conjugate (CA-NP30) was fabricated. BALB/c mice were immunized actively with CA-NP30 to evaluate its effects of protective immunity on mice. The serum levels of specific IgG,IgG1 and IgG2a antibodies against NP30 and the concentrations of IFN-γ and IL-4 in supernatant of splenocytes were determined via ELISA. Results Nanoparticle CA could enhance significantly the protective immunity of NP30 against infection of Schistosoma japonicum and the worm reduction rose from 36.0% (NP30 alone) to 52.6%. The serum levels of specific IgG,IgG1 and IgG2a antibodies against NP30 increased remarkably,as compared with those of the group immunized with NP30 alone. The concentration of IFN-γ in supernatant of splenocyte was drastically elevated [the groups immunized with CA-NP30 and NP30 alone were (493.80±400.74) pg/ml and (39.03±39.58) pg/ml,respectively],but the concentration of IL-4 showed no significant difference from that of NP30 alone [(27.94±9.84) pg/ml vs (27.28±14.44) pg/ml]. Conclusions Nanoparticle CA could act as a vaccine adjuvant of anti-idiotypic antibody NP30 against schistosomiasis. The mechanism could be that CA-NP30 enhances humoral and cellular immune responses in mice. Background The development of new adjuvants for human use has been the focus of attention. This study’s aim is to explore the possibility of using nanoparticle Ca nanoparticles (CA) as a vaccine adjuvant of anti-idiotypic antibody NP30 against schistosomiasis and its protective mechanisms. Methods Nanoparticle CA-NP30 conjugate (CA-NP30) was fabricated. BALB/c mice were immunized actively with CA-NP30 to evaluate its effects of protective immunity on mice. The serum levels of specific IgG,IgG1 and IgG2a antibodies against NP30 and the concentrations of IFN-γ and IL-4 in supernatant of splenocytes were determined via ELISA. Results Nanoparticle CA could enhance significantly the protective immunity of NP30 against infection of Schistosoma japonicum and the worm reduction rose from 36.0% (NP30 alone) to 52.6%. The serum levels of specific IgG,IgG1 and IgG2a antibodies against NP30 increased remarkably,as compared with those of the group immunized with NP30 alone. The concentration of IFN-γ in supernatant of splenocyte was drastically elevated [the groups immunized with CA-NP30 and NP30 alone were (493.80±400.74) pg/ml and (39.03±39.58) pg/ml,respectively],but the concentration of IL-4 showed no significant difference from that of NP30 alone [(27.94±9.84) pg/ml vs (27.28±14.44) pg/ml]. Conclusions Nanoparticle CA could act as a vaccine adjuvant of anti-idiotypic antibody NP30 against schistosomiasis. The mechanism could be that CA-NP30 enhances humoral and cellular immune responses in mice.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2004年第1期83-87,共5页 中华医学杂志(英文版)
基金 ThisstudywassupportedbytheNationalNaturalScienceFoundationofChina (No 3 0 170 83 6)andtheCreativeFoundationofNanjingMedicalUniversity (No CX2 0 0 0 0 1)
关键词 nanoparticle·schistosomiasis·anti-idiotypic antibody·vaccine adjuvant nanoparticle·schistosomiasis·anti-idiotypic antibody·vaccine adjuvant
  • 相关文献

参考文献10

  • 1CoutelierJP,vanderLogtJTM,HeessenFWA etal.IgG2arestrictionofmurineantibodieselicitedbyviralinfections[].The Journal of Experimental Medicine.1987
  • 2HocartMJ,MackenzieJS,StewartGA.TheimmunoglobulinGsubclassresponsesofmicetoinfluenzaAvirus:theeffectofmousestrain andtheneutralizingantibodiesofindividualproteinA$Cpurifiedsubclassantibodies[].Journal of General Virology.1989
  • 3SinghM,CarlsonJR,BrionesM etal.AcomparisonofbiodegradablemicroparticlesandMF59assystemicadjuvantsforrecombinantIgDfromHSV 2[].Vaccine.1998
  • 4KatoH,ShibamoM.Relationshipbetweenhemolyticactivityandabsorptioncapacityofaluminumandcalciumphosphateasimmunologicaladjuvantsforbiologicals[].Microbiology and Immunology.1994
  • 5NagelJE,WhiteC,LinMS etal.IgEsynthesisinmanII ComparisonoftetanusanddiphtheriaIgEantibodyinallergicandnon allergicchildren[].The Journal of Allergy and Clinical Immunology.1979
  • 6Kreuter J,Haenzel I.Mode of action of immunological adjuvants: some physicochemical factors influencing the effectivity of polyacrylic adjuvants[].Infection and Immunity.1978
  • 7Feldkamp JR,White JL,Hem SL.Effect of surface charge and particle size on gel structure of aluminum hydroxycarbonate gel[].Journal of Pharmacological Sciences.1982
  • 8Snapper CM,Paul WE.Interferon-γ and B cell stimulatory factor-1 reciprocally regulate Ig isotype production[].Science.1987
  • 9Neuberger MS,Rajewsky K.Activation of mouse complement by monoclonal mouse antibodies[].European Journal of Immunology.1981
  • 10Neefjes JJ,Mornburg F.Cell biology of antigen presentation[].Current Opinion in Immunology.1993

同被引文献56

引证文献5

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部